Clinical trials: Hormone Imbalance
Hyperparathyroidism
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
We are investigating whether, after surgical cure of primary hyperparathyroidism, alendronate provides even greater beneficial skeletal effects than parathyroidectomy alone.
- Trial name
- AlenPostPara (NCT00359385)
- Testing
- Alendronate 70mg weekly
- Where
- United States
- Sponsor
- Columbia University
Empaglifozin, Physiological Effects of Drugs
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Background: The drug empagliflozin treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood.
- Conditions
- Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT03852901
- Testing
- empagliflozin (Jardiance) 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Aging (NIA)
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
Tolvaptan Versus Fluid Restriction in SIADH
Context. The relevance of hyponatremia has been acknowledged by guidelines from the United States of America (2013) and Europe (2014). However, treatment recommendations differ due to limited evidence. Objective.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Pituitary
- Trial name
- NCT04119206
- Volunteers
- 334 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Menstrual Cycle Disorder, Menstrual Symptoms
Evaluation of The Cycle SyncingⓇ Method: A 12-Week Virtual Clinical Trial
This 12-week, 100% virtual single-group open-label trial evaluates the Cycle SyncingⓇ Method using the MyFLO app, MIRA hormonal monitoring, and continuous glucose monitoring to assess reduction in menstrual cycle symptom burden…
- Conditions
- Menstrual Cycle Disorder, Menstrual Symptoms, Hormonal Imbalance
- Trial name
- NCT07286136
- Testing
- MyFLO App
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- FLO LIVING, LLC
Hypocalcemia, Thyroid
Is Correcting Total Serum Calcium Levels Important After Thyroidectomy
This study is designed as a prospective non-randomized longitudinal single- center cohort study to evaluate the importance of correcting total serum calcium levels.
- Conditions
- Hypocalcemia, Thyroid, Parathyroid Dysfunction, Calcium Disorder
- Trial name
- NCT04304573
- Testing
- Total serum calcium blood test
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- University Hospital Sestre Milosrdnice
Inappropriate ADH Syndrome, Hyponatremia
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
To assess the efficacy of SR121463B in correcting hyponatremia in patients with syndrome of inappropriate antidiuretic secretion (SIADH).To assess the long-term efficacy of SR121463B in maintaining normal levels of serum sodium…
- Trial name
- SIADH (NCT00264927)
- Testing
- SR121463B
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 77 people
- Sponsor
- Sanofi
Secondary Hyperparathyroidism, Renal Insufficiency, Chronic
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
The purpose of this study is to observe the effectiveness and safety of the use of a low initial dose regime (iPTH/100) in chronic kidney disease patients with secondary hyperparathyroidism (PTH>300pg/mL) and that require…
- Conditions
- Secondary Hyperparathyroidism, Renal Insufficiency, Chronic, Parathyroid Hormone, Hemodialysis
- Trial name
- NCT00891813
- Testing
- Zemplar (paricalcitol)
- Where
- 3 sites in Peru
- Volunteers
- 100 people
- Sponsor
- Abbott
Inappropriate ADH Syndrome, Hyponatremia
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
To determine the long-term safety and tolerability of SR121463B in patients with syndrome of inappropriate antidiuretic secretion (SIADH).
- Trial name
- SIADH Safety (NCT00264914)
- Testing
- SR121463B
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 57 people
- Sponsor
- Sanofi
Cushing Disease Due to Increased ACTH Secretion
Combination Osilodrostat and Cabergoline in Cushing's Disease
Cushing disease remains a challenging endocrine disorder in which persistent or recurrent hypercortisolism often requires medical therapy after surgery or when surgery is not feasible.
- Trial name
- COSCA-ECD (NCT07603466)
- Testing
- osilodrostat, osilodrostat and cabergoline
- Where
- 5 sites in Iraq
- Volunteers
- 50 people
- Sponsor
- University of Basrah
Hyperparathyroidism, Hypercalcemia
Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects
The purpose of this study is to assess if subjects with hyperparathyroidism with normal serum calcium levels have different responses in the calcium regulating hormonal handling compared to a) patients with primary…
- Trial name
- NCT01042626
- Testing
- Oral peptones load
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Eastern Piedmont
Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder
Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).
This is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism in dialysis-dependent patients.
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder, Dialysis, Hypocalcemia
- Trial name
- TeriCa (NCT04750460)
- Testing
- Teriparatide
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Saint Petersburg State University, Russia
Hyponatremia
Study of Ascending Levels of Tolvaptan in Hyponatremia
The purpose of this study was to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this…
- Trial name
- SALT2 (NCT00201994)
- Testing
- Tolvaptan
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hormone Disturbance
An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Hormonal Imbalance
This is an open-label observational trial to study the effectiveness of a commercial dietary supplement and its effect on common symptoms of normal menstrual discomfort.
- Trial name
- NCT05328609
- Testing
- Semaine Hormonal Imbalance & The Daily
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Semaine Health
Hypoparathyroidism, Hypocalcemia
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
This randomized crossover study will evaluate the safety, efficacy, and pharmacodynamics of synthetic human PTH 1-34 (PTH) delivered by an insulin pump (omnipod) compared with twice- daily subcutaneous injections.
- Conditions
- Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Trial name
- NCT00743782
- Testing
- Synthetic Human Parathyroid Hormone 1-34 pump
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hyponatremia
Saline Infusion Test in Hyponatremia
Observational study of biochemical volume biomarker levels in response to a standardized intravenous isotonic saline infusion in patients with hyponatremia.
- Trial name
- SITH (NCT06498856)
- Testing
- Isotonic saline infusion
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Akershus
Hypothyroidism
Clinical Efficacy of Darqeen Capsule for the Management of Hypothyroidism Associated with Female Reproductive Hormonal Imbalance
STUDY OBJECTIVES 1. To assess the safety of Darqeen capsule for the management of Hypothyroidism 2. Evaluate the efficacy of Darqeen capsule for the management of Hypothyroidism 3.
- Trial name
- NCT06826248
- Testing
- Darqeen Capsule
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Hamdard University
Hyponatremia, Inappropriate ADH Syndrome
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH.
- Trial name
- AQUARIST1 (NCT00728091)
- Testing
- Satavaptan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sanofi
Ketosis
Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More
This study aims to address two key aspects. First, the suitability of selecting a specific sampling site for BHB measurement in patients and research, as well as potential differences between capillary and venous blood…
- Trial name
- NCT06053138
- Testing
- Ketone monoester
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Central Jutland Regional Hospital
Hyperparathyroidism, Secondary
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
- Trial name
- NCT01932970
- Testing
- Etelcalcetide
- Where
- 40 sites in United States
- Volunteers
- 158 people
- Sponsor
- Amgen
Traumatic Brain Injury
Prevalence, Severity, Risk Factors, and Prognostic Value of Hyponatremia in Patients With Traumatic Brain Injury
Hyponatremia (HN) is the most common electrolytic disorder in the traumatic brain injury (TBI) population, found in 17 to 51% of patients according to the series.
- Trial name
- WATERWAR (NCT05301049)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Montpellier